Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atx-898 + fulvestrant + ribociclib
- Development stage
- Unknown
- Lead developer
- Antares Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
ATX-898 + fulvestrant + ribociclib is an investigational triplet combination therapy being evaluated for the treatment of advanced solid tumors, including ovarian, gynecologic, and HR+/HER2- breast cancers. The regimen combines **ATX-898**, a novel small molecule precision oncology agent developed by Antares Therapeutics (a spin-out of Scorpion Therapeutics), with two established anti-neoplastic agents: **fulvestrant** and **ribociclib**. Fulvestrant is a selective estrogen receptor degrader (SERD) that binds to and destabilizes the estrogen receptor, while ribociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which are critical regulators of the cell cycle. By simultaneously targeting the estrogen signaling pathway and the cell cycle machinery, this combination aims to enhance therapeutic efficacy and overcome resistance mechanisms in hormone-driven malignancies. The combination is currently being studied in a Phase 1/2 open-label clinical trial (NCT06465290).
- Other names
- ATX-898 + fulvestrant + ribociclib
02
Targets
CDK4 (Cyclin-dependent kinase 4)ESR2 (ERβ)ESR1 (ERα)CDK9 (Cyclin-dependent kinase 9)CDK6 (Cyclin-dependent kinase 6)
Beyond the preview
Go deeper on atx-898 + fulvestrant + ribociclib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atx-898 + fulvestrant + ribociclib.